根据名称进行药物检索

Actiq 与 Parnate

Actiq 与 Parnate互相作用以及同时服用的可能性。

检测结果:

Actiq <> Parnate

现实性: 01.10.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用苯环丙胺一起芬太尼不建议。结合这些药物可以增加风险的呼吸抑郁症低血压力和稀少，但严重的疾病叫做血清素综合症，其中可能包括的症状，如混乱、幻觉、扣押、极端变化血压，心率增加、发烧、多汗、颤抖或颤抖、视力模糊，肌肉痉挛或僵硬、震颤、不协调、胃痉挛、恶心、呕吐、腹泻。严重的情况下可能导致昏迷甚至死亡。在一般情况下，应至少等待14天之后，停止苯环丙胺在你开始处理与芬太尼。相反，如果你最近已经在芬太尼和现在开始处理与苯环丙胺，你应该检查你的医生或药剂师看到你多久之前应等待这是为你的安全使用苯环丙胺，因为某些药物可能需要一段时间才能明确自己的身体。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

禁忌:共同给予的单胺氧化酶抑制剂(单胺氧化抑制剂)与某些阿片类药物已经与罕见的报告的严重和致命的不良反应。似乎有两种类型的相互作用，一种兴奋性和有抑郁症的一种。症状的兴奋性反应可能包括鼓动、头痛、发汗解表,次高烧、冲洗、颤抖、肌阵挛、刚性、震颤、腹泻、高血压、心动过速、癫痫发作和昏迷。死亡已经发生，在某些情况下。的确切机制的相互作用是未知的，但可能涉及过多的血清素的活动的中枢神经系统(即中，血清素综合征)。相互作用是不可预知的，并已上报主要哌替啶或芬太尼和各种单胺氧化抑制剂（包括苯乙肼、苯环丙胺,利奈唑,氯贝胺和吉兰. 致命的一次高烧和高血压也已观察到，在动物研究与哌替啶和苯乙肼或者痢特灵. 与此相比，症状的抑郁的反应可能干，从中枢神经系统的增强效果的单胺氧化抑制剂以及包括呼吸抑郁症、发绀、低血压和昏迷。

管理：哌替啶和芬太不应该使用单胺氧化抑制剂或其他代理商，拥有单胺氧化酶抑制剂的活动(例如痢特灵，利奈唑胺、亚甲基蓝色，丙卡巴肼). 一些制造商的单胺氧化抑制剂还contraindicate伴随使用的丙氧芬和美沙酮由于其可能的素的影响。至少14天应之间停止的单胺氧化酶抑制剂疗法和治疗开始与这些阿片类药物。虽然吗啡也可能有明显的中枢神经系统的相互作用与单胺氧化抑制剂，它通常被认为是一个更安全的替代治疗的患者对与单胺氧化抑制剂，需要麻醉镇痛剂。敏感性测试应该是执行在它重复，小增量剂量的吗啡是给予过程的几个小时，同时总体的临床状态和至关重要的迹象是认真的监测。

来源

Zornberg GL, Hegarty JD "Adverse interaction between propoxyphene and phenelzine." Am J Psychiatry 150 (1993): 1270-1
Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554
"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA, North Wales, PA.
"Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.
Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5
Upton R, Graff A, Williamson E, et al. "American Herbal Pharmacopoeia and Therapeutic Compendium. Monograph printed in Herbalgram." Herbalgram 40 (1997): 1-38(monograph)
Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82
Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):
Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62
De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5
Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36
"Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7
Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7
Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6
"Product Information. Actiq (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.
"Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
"Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5
Vigran IM "Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride." JAMA 187 (1964): 953-4
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):
Cerner Multum, Inc. "Australian Product Information." O 0
Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8
Youssef MS, Wilkinson PA "Epidural fentanyl and monoamine oxidase inhibitors." Anaesthesia 43 (1988): 210-2
Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8
"Product Information. Eldepryl (selegiline)." Somerset Pharmaceuticals Inc, Tampa, FL.
Starr C "Interaction between pethidine and selegiline." Lancet 337 (1991): 554
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
"Product Information. Meperidine Hydrochloride Injection, USP (meperidine)" Astra-Zeneca Pharmaceuticals, Wilmington, DE.
"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.
Michaels I, Serrins M, Shier NQ, Barash PG "Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors." Anesth Analg 63 (1984): 1041-4
"Product Information. Methylene Blue (methylene blue)." American Regent Laboratories Inc, Shirley, NY.
"Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2
Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
Garbutt JC "Potentiation of propoxyphene by phenelzine." Am J Psychiatry 144 (1987): 251-2